Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 3/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167964 | 0.87 | KDR (0.68) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL18519134 | 0.85 | KDR (0.48) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL6014106 | 0.83 | RAF1 (0.58) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL6014711 | 0.82 | KDR (0.49) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL14208186 | 0.82 | KDR (0.50) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL6014835 | 0.82 | MMP13 (0.64) | KDRBRAFRAF1EPHX2P2RX3 | |
| SCHEMBL903580 | 0.82 | P2RX3 (0.53) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL15295583 | 0.81 | RAF1 (0.55) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL257959 | 0.81 | RAF1 (0.50) | KDRBRAFRAF1MAPK14P2RX3 | |
| SCHEMBL6014158 | 0.78 | RAF1 (0.54) | KDRBRAFRAF1EPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1690853-B1 | Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-03-10 | — | — | EP | disclosed |